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Abstract
Background: The human papillomavirus (HPV) E2 protein is a multifunctional DNA-binding protein. The transcriptional
activity of HPV E2 is mediated by binding to its specific binding sites in the upstream regulatory region of the HPV
genomes. Previously we reported a HPV-2 variant from a verrucae vulgaris patient with huge extensive clustered
cutaneous, which have five point mutations in its E2 ORF, L118S, S235P, Y287H, S293R and A338V. Under the control of
HPV-2 LCR, co-expression of the mutated HPV E2 induced an increased activity on the viral early promoter. In the
present study, a series of mammalian expression plasmids encoding E2 proteins with one to five amino acid (aa)
substitutions for these mutations were constructed and transfected into HeLa, C33A and SiHa cells.
Results: CAT expression assays indicated that the enhanced promoter activity was due to the co-expressions of
the E2 constructs containing A338V mutation within the DNA-binding domain. Western blots analysis
demonstrated that the transiently transfected E2 expressing plasmids, regardless of prototype or the A338V mutant,
were continuously expressed in the cells. To study the effect of E2 mutations on its DNA-binding activity, a serial of
recombinant E2 proteins with various lengths were expressed and purified. Electrophoresis mobility shift assays
(EMSA) showed that the binding affinity of E2 protein with A338V mutation to both an artificial probe with two E2
binding sites or HPV-2 and HPV-16 promoter-proximal LCR sequences were significantly stronger than that of the
HPV-2 prototype E2. Furthermore, co-expression of the construct containing A338V mutant exhibited increased
activities on heterologous HPV-16 early promoter P97 than that of prototype E2.
Conclusions: These results suggest that the mutation from Ala to Val at aa 338 is critical for E2 DNA-binding and
its transcriptional regulation.
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Background
Human papillomaviruses (HPVs) are small, double-
stranded DNA viruses that infect the mucosal epithelial
tissues of anogenital tract, oral cavity and upper alimen-
tary tract, as well as cutaneous epithelial tissues of
hands, feet and trunks. HPVs have been grouped into
cutaneous type that causes cutaneous warts and epider-
modysplasia verruciformis, and mucosal type that predo-
minantly induces benign and malignant lesions of the
genital tract, in which HPV-2 has been frequently asso-
ciated with verrucae vulgaris [1]. HPV-2 genome is
composed of eight open reading frames (ORFs) encod-
ing the regulatory proteins essential for completion of
the viral life cycle and the structural components of the
virion, respectively [2].
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provided the original work is properly cited.HPVs’ E2 proteins are believed to control the tran-
scriptions of viral genes through binding to the specific
sites in viral DNA, multiple copies of which are found
in the viral upstream regulatory regions (URRs) [3]. The
HPV E2 protein can function as either a repressor or an
activator of the early gene transcription, depending on
t h el o c a t i o no fE 2b i n d i n gs i t e si nt h ev i r a lr e g u l a t o r y
region as previously demonstrated for genital HPVs [4].
The structure of the E2 protein resembles a typical tran-
scription factor, with an amino-terminal transcriptional
activation domain (TAD) and a carboxyl-terminal DNA-
binding/dimerization domain (DBD), separated by a
v a r i a b l eh i n g er e g i o n[ 2 ] .T h eE 2p r o t e i ne x i s t si ns o l u -
tion and binds to the target DNA as a dimmer. The
HPV-16 E2-DBD forms a dimeric b-barrel, with each
subunit contributing an anti-parallel 4-stranded b-sheet
“half-barrel” [5]. Several studies showed that E2 acts as
a transactivator at low concentrations, while as a repres-
sor at high concentration. Recently, it has been reported
that the locations of E2 binding sites are important for
transcriptional repression, independent of binding affi-
nities [6].
Besides being a transcriptional regulator in the life-
cycle of virus, E2 protein is believed to play an impor-
tant role in the carcinogenesis of HPV-associated can-
cers. The HPV genome can exist in the malignant cells
in two forms, integrated into the host chromosome or
episomal DNA. The majority of HPV-associated cancers,
especially cervical carcinoma, contain integrate HPV
DNA [7]. Usually, integration of viral genome into host
chromosome results in disruptions of E2 and E1 ORFs,
leading to an increased transcription from the viral early
promoter and elevated expression of viral oncogenes E6
and E7 [7,8]. About 15-20% HPV-positive cervical can-
cers contain intact HPV genomes in extrachromosomal
state. Various point mutations or deletions in the HPV
genome were reported to be related to the viral onco-
genesis potential, e.g. in the long control region (LCR)
[9], E2 and E1 ORFs [10]. Previously we reported a ver-
rucae vulgaris patient with huge extensive clustered
cutaneous who was confirmed to be infected by a HPV-
2 variant [11,12]. Several point mutations were detected
in the LCR of this HPV-2 variant that lead to an
increased promoter activity. In addition, five point
mutations were found within the E2 ORF. Expression of
the E2 mutant exhibited increased activities on the viral
early promoter as compared with the prototype E2 [13].
In order to gain insight into the potential influences of
these mutations within E2, we constructed a series of
mammalian and prokaryotic expressing plasmids encod-
ing E2 proteins with one to five amino acid (aa) substi-
tutions. Upon co-transfection with a CAT reporter
under the control of HPV-2 LCR, the E2 construct con-
taining the A338V mutation within the DNA-binding
domain functioned as a transactional activator instead of
repressor. Electrophoretic mobility shift assays (EMSA)
demonstrated that the ability of E2 protein with A338V
mutation bind a double-stranded DNA sequence con-
taining two E2 binding sites is markedly stronger than
HPV-2 prototype E2. The binding affinity of the E2
A338V mutant for the promoter-proximal LCR
sequences of HPV-2 and HPV-16 were also significantly
increased. Structural analyses indicated that the muta-
tion A338V located in the region of beta barrel. These
results imply that the mutation A338V is critical for the
E2 DNA-binding and promoter regulation.
Results
The A338V mutation within the HPV-2 E2 DNA-binding
domain is critical for E2 transcriptional regulation activity
on the HPV-2 early promoter
To assess the effect of the point mutations within E2 on
its transcriptional activity, a series of HPV-2 E2 mam-
malian expressing plasmids were constructed. These
include the point mutations within the E2 transactiva-
tion, hinge and DNA-binding regions. In addition, two
plasmids expressing truncated E2 proteins were also
generated (Figure 1A). To detect expression of HPV-2
E2 from the transiently transfected plasmids in the cul-
tured cells, HeLa and C33A cells transfected with
pcDNA-E2-proto and pcDNA-E2-A338V were harvested
24, 48 and 72 h post-transfection, respectively. The pre-
sences of HPV E2 proteins in cell lysates were con-
firmed by Western blot wi t haH P V - 2E 2s p e c i f i c
monoclonal antibody (mAb) prepared with a full-length
recombinant HPV-2 E2 protein as immunogen, which
recognized the segments of N-terminus and hinge
region of E2 protein (unpublished) (Figure 1B). In addi-
tion, E2 expressing in HeLa cells were also evaluated by
Western blots after co-transfection of the HPV-2 E2
plasmids with the pCAT-LCR (L) reporter plasmid. As
shown in Figure 1C, the full-length E2 (43 KD) and N-
terminal E2 (22 KD) were detected, whereas no signal
was observed for the C-terminal E2.
Under our experimental condition, transfection of the
blank CAT reporter vector (pBL-CAT6) did not induce
detectable CAT expression (data not shown). Consistent
with previous observations in HeLa cells containing
HPV-18 genome [13], co-transfection of pcDNA-E2-
proto significantly reduced the HPV-2 LCR driven CAT
expression (Figure 2A, pcDNA-E2-proto), whereas co-
transfection of pcDNA-E2-Mut significantly increased
the CAT expression (pcDNA-E2-Mut). Co-transfected
with the plasmids encoding N- (pcDNA-E2-N) and C-
terminal (pcDNA-E2-C) E2 resulted in significantly
higher CAT expressions than that with the plasmid
encoding full-length prototype E2. Transfection of the
plasmids expressing single point mutation within the
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Page 2 of 13transactivation domain (Figure 2A, pcDNA-E2-L118S)
and the hinge region (Figure 2A, pcDNA-E2-S235P)
resulted in comparable CAT expressions as that of pro-
totype E2, while pcDNA-E2-L118S/S235P induced a
relatively higher CAT expression. Interestingly, transient
transfection of pcDNA-E2-A338V containing a single
point mutation in the E2 DNA-binding domain led to a
significantly increased CATe x p r e s s i o nt h a tw a se v e n
slightly higher than that of pcDNA-E2-Mut. In contrast,
transfection of pcDNA-E2-Mut (-) containing all four
point mutations but A338V caused a significant repres-
sion of CAT expression that was comparable with
Figure 1 Expressions of various HPV-2 E2 proteins in the
cultured cells. A. Schematic structures of the full-length E2 and
various mutated E2. The black crosses indicate the amino acid
exchanges of these mutants. B. HeLa (left panel) or C33A (right
panel) cells were either mock transfected or transfected with 500 ng
of pcDNA-E2-proto or pcDNA-E2-A338V as indicated. Cells were
harvested 24, 48 or 72 h post-transfection. The prepared cells
extracts were separated by 15% SDS-PAGE, transferred to
nitrocellulose membrane and probed with E2 or b-actin antibody as
indicated. Exposition time was 5 min for E2 and 2 min for b-actin.
The blot shown is a representative experiment among three
experiments. C. 500 ng of various E2 constructs were co-transfected
with 2 μg CAT reporter plasmid pCAT-LCR into HeLa cells,
respectively. Cells were harvested 48 h post-transfection. The blot
shown is a representative experiment among three experiments.
The blots of E2, E2-N and b-actin are indicated on the left and
relative molecular weights are arrowed on right
Figure 2 The influences of various HPV-2 E2 constructs on the
promoter activity under control of the LCR of HPV-2. A. The
relative CAT expressions co-transfected with different E2 expressing
plasmids in HeLa cells. The schematic structure of HPV-2-LCR cloned
in the CAT reporter plasmid pBL-CAT6 is shown above. HPV-2-LCR
covers the sequences from nt 6934 to 134. The positions of TATA
box and four potential E2 binding sites are indicated with the
starting nucleotide (nt) below. HeLa cells were transfected with 2
μg of plasmid pCAT-LCR and 500 ng of either mock plasmid
(pcDNA3.1) or the plasmids for various E2 constructs (as indicated).
1 μg pCMV-b-galactosidase was transfected as internal control. Cells
were harvested 48 h after transfection. The expressions of CAT and
b-galactosidase were determined. The CAT expression each
preparation was normalized with its b-galactosidase value. The
relative CAT expressions are averaged from at least three
independent experiments and presented relative to that of
pcDNA3.1. Data are represented as mean ± SEM. B. The relative CAT
expressions co-transfected with different E2 expressing plasmids in
C33A and SiHa cells. C33A and SiHa cells were transfected with 2
μg of plasmid pCAT-LCR and 500 ng of either mock plasmid
(pcDNA3.1) or the plasmids for various E2 constructs (as indicated).
1 μg pCMV-b-galactosidase was transfected as an internal control.
The relative CAT expressions are averaged from at least three
independent experiments in C33A and SiHa cells and presented
relative to that of pcDNA3.1. Data are represented as mean ± SEM
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A338V mutation within the DNA-binding domain is
essential for the E2 repression activity.
Next, we examined the transcriptional activity of E2
with A338V mutation the HPV-negative cervical cancer
cell lines C33A and the HPV-16 genome-containing
SiHa cells. Consistent with the results in HeLa cells,
under the control of HPV-2 LCR, co-expression of
pcDNA-E2-proto and pcDNA-E2-Mut (-) led to
obviously low CAT expressions compared with mock,
whereas co-expressions of pcDNA-E2-Mut and pcDNA-
E2-A338V caused high CAT expressions (Figure 2B).
Notably, in pcDNA-E2-A338V-transfected cells, the
relative CAT expression was higher than that of mock.
These results imply that the transcriptional repression
activity of E2 mutant A338V is independent of the
endogenous HPV genome.
The A338V E2 mutant increased the binding capacity to
the DNA sequences containing conservative E2 binding
sites in vitro
To explore the mechanism for derepression on the
HPV-2 promoter activity caused by the mutation
A338V, a serial of recombinant E2 proteins were
expressed and purified in E. coli. Figure 3A summarizes
the E2 proteins in different contexts, including one con-
struct of E2 transactivation domain, two constructs of
E2 DNA-binding region, four constructs of E2 hinge
region and DNA-binding domain and four constructs of
full-length E2. All proteins were expressed in soluble
form as GST-fusions (Figure 3B).
Using the biotin-labeled double-stranded oligo HPV-
E2BS containing two E2 protein binding sites (E2BS),
the DNA-binding activities ofd i f f e r e n te x p r e s s e dE 2
proteins were evaluated by EMSA. The specificity of
oligo HPV-E2BS for HPV E2 protein was first evaluated
by competition experiments with homologous or hetero-
logous unlabeled oligos. Compared with the clear DNA-
protein complex formation in the mixture of HPV-2 E2
and oligo HPV-E2BS, addition of the excessive cold
homologous oligo instead of the heterologous oligo T7
(Figure 4A, left panel). To get more evidences on the
specificity of the binding of oligo HPV-E2BS with E2
protein, the recombinant HPV-2 E2 was incubated with
a mAb against HPV-2 E2 prior to EMSA. Along with
t h er e d u c t i o n so ft h es i g n a l so ft h eD N A - E 2c o m p l e x e s
i nt h ep r e s e n c eo fm A ba n t i - E 2 ,o b v i o u ss u p e r s h i f t s
were detected (Figure 4A, right panel). These results
indicate the interaction between oligo HPV-E2BS and
E2 protein is specific.
In the context of E2 binding domain, both prototype
E 2a n dt h eA 3 3 8 Vm u t a n tE 2f o r m e dp r o t e i n - D N A
complexes with the probes in a dose-dependent manner.
Interestingly, the binding activity of E2 mutant was
significant stronger than that of prototype E2 (Figure
4B). To confirm this phenomenon, four E2 proteins cov-
ering E2 hinge region and DNA-binding region were
employed into EMSA. Figure 4C showed that the DNA-
binding activity of E2-HC-A338V was stronger than that
of prototype E2-HC. Additionally, E2-HC-Mut with
A338V and other three point mutations in hinge region
showed similar DNA-binding activity as E2-HC-338 V,
while E2-HC-Mut (-) with only three mutations in hinge
region caused similar DNA-binding activity as prototype
E2-HC. As expected, neither GST nor E2 transactivation
domain (E2-N), formed a complex in EMSA. Similar
manner were observed in the EMSA in the context of
full-length E2 protein, in which two constructs contain-
ing the A338V mutation (E2-FL-A338V and E2-FL-Mut)
formed more obvious protein-DNA complexes than the
other two constructs without the A338V mutation (E2-
FL and E2-FL-Mut (-)), regardless of having the point
mutations in the transactivation domain and hinge area
(Figure 4D). These results highly suggest that the substi-
tution of Ala to Val at residual 338 in HPV-2 E2 protein
influences critically its DNA-binding affinity.
E2 DNA-binding affinities were influenced by the length
of the E2 peptides
From the EMSA results shown in Figure 4, it seemed
that the DNA-binding activities of E2 were also affected
by the length of the peptides. To address this possibility,
the same molar number of E2 proteins in three different
lengths was mixed with biotin-labeled oligos. With 12.5
fM of oligos, only the E2-C construct formed detectable
protein-DNA complexes (Figure 5, left panel). The pro-
tein-DNA complexes of E2-HC constructs were clearly
observed when the amount of oligo was increased to
125 fM, while that of E2-C became much stronger (Fig-
ure 5, middle panel). When the amounts of oligo
increased to 250 fM, the protein-DNA complexes
formed by the constructs of E2-FL became visible (Fig-
ure 5, right panel). In addition, the A338V E2 formed
abundant protein-DNA complex in all three lengths of
E2 peptides tested and in all three concentrations of
oligo. These results suggest that the transactivation
domain and the hinge region of E2 play a negative role
in its DNA binding affinity.
The A338V E2 mutants increased the binding affinity to
the promoter-proximal LCR sequences of HPV-2 and HPV-
16
To evaluate the DNA-binding activities of E2 with
A338V to the wild-type HPV sequences, the biotin-
labeled double-stranded oligos derived from the
sequences of prototype HPV-2 and HPV-16 LCRs,
which contained two E2 protein binding sites, were
mixed with equal amount of the different recombinant
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Page 4 of 13Figure 3 Expressions and purifications of various recombinant HPV-2 E2 proteins. A. Schematic structures of the full-length E2 and various
mutated E2. The mutations are marked by the black crosses. B. 15% SDS-PAGE assays of various purified recombinant E2 proteins. Full length
and various mutated E2 protein with GST tag were expressed in E. coli BL21 and purified with Glutathione sepharose 4B Agarose. 0.5 μg of each
purified E2 protein was loaded on 15% SDS-PAGE and stained by coomassie brilliant blue. Each purified protein is indicated on the tops of the
graphs. M: Protein molecular markers. The molecular sizes are shown on the left
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Page 5 of 13Figure 4 Evaluations for DNA-binding capacities of various HPV-2 E2 proteins with oligo HPV-E2BS by EMSA. A. Specificity assays of the
molecular binding of oligo HPV-E2BS with recombinant HPV-2 E2. Left panel: Competition assays. 250 fM biotin-labeled oligonucleotide probe
HPV-E2BS were mixed with 1 μg recombinant protein HPV-2 E2-FL, competed with 50-, 100-, and 500-fold excesses of homologous oligo (HPV-
E2BS) and 500-fold excesses of heterologous oligo (T7). Oligonucleotide T7 represents E. coli T7 promoter-specific double-stranded sequences (5’-
TCGATAATACGACTCACTATAGGGAGAAGATC-3’). Right panel: Supershift assay with mAb anti-HPV-2 E2. 7 μg recombinant HPV-2 E2-FL was
incubated with 1 μl mAb against HPV-E2 at RT, prior to mixing with 250 fM biotin-labeled probe HPV-E2BS. The E2-DNA complexes and the
supershifts are indicated by arrows. F: free probe. B. EMSA of various constructs of E2-C. C. EMSA of various constructs of E2-HC. D. EMSA of
various constructs of E2-FL. 250 fM biotin-labeled probe HPV-E2BS were mixed with different amounts of various E2 proteins. The concentrations
of various E2 protein were indicated in the bottom of the graphs. The protein-DNA complexes were separated in 6.5% PAGE gels (Left) indicated
by arrows marked E2-FL, E2-HC and E2-C, respectively. The competition assays were performed in the presences of 500-fold excess of unlabeled
probe HPV-E2BS prototype (Middle). F: free probe. The binding capacities of various E2 proteins (Figure 4B, C and D) were evaluated by
densitometric quantification of the signal of each complex with computer-assisted software Image TotalTech. The average values are calculated
from three independent tests and presented with as mean ± SD (Right)
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Page 6 of 13Figure 5 Comparative analyses of DNA-binding activities between the HPV-2 prototype E2 (represented as E2) and mutated E2 at the
position of residual 338 (represented as E2-A338V). A: oligo HPV-E2BS; B: oligo HPV-2 prototype; C: oligo HPV-16 prototype. Equally molar
amounts (1.3 × 10
-11 mol) of E2 and E2-A338V proteins in three different constructs were mixed the individual biotin-labeled probes and the
protein-DNA complexes were separated in 6.5% PAGE gels. Lane 1 and 4: E2-FL protein; Lane 2 and 5: E2-HC; Lane 3 and 6: E2-C. The probe
amounts used in EMSA are indicated at the bottom of the graphs and the protein amounts are shown above the graphs. The protein-DNA
complexes of the preparations are indicated by arrows marked E2-C (lane 1 and 4), E2-HC (lane 2 and 5) and E2-FL (lane 3 and 6), respectively. F:
free probe
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Page 7 of 13prototype and mutated E2 proteins and assessed in
EMSA. Consistent with results shown in Figure 4, the
A338V E2 mutants showed clearly stronger binding affi-
nities to both HPV-2 (Figure 5B) and HPV-16 (5 C) oli-
gos than the HPV-2 prototype E2, in the context of
either full-length or truncated forms. No difference was
observed in the binding affinity of HPV-2 E2 to the LCR
sequences of homologous or heterologous HPV geno-
types. These results show that A338V E2 mutant has
stronger binding affinity to the promoter-proximal LCR
sequences of wild-type HPVs. E2 C-terminus (E2-C)
possessed much stronger binding activities to HPV-2
and HPV-16 LCR than E2-HC and E2-FL, which were
coincident well with the binding tendency of different
E2 in length shown in Figure 4B, C and 4D. The multi-
ple bands at higher molecular weight position in the
gels (Figure 4C, D and 5) may represent the dimmers of
the E2 proteins.
Co-expressions of HPV-2 E2 mutants with A338V
induced more active activity on heterologous HPV-16
early promoter P97 than the HPV-2 prototype E2.
In order to figure out whether the E2 mutation A338V
induced similar effectiveness on viral early promoter of
heterologous genotype HPV, a CAT-reporter plasmid
under the control of HPV-16 LCR was co-transfected
with same amount of various HPV-2 E2 expressing plas-
mids, including pcDNA-E2-proto, pcDNA-E2-Mut(-),
pcDNA-E2-Mut and pcDNA-E2-A338V, respectively.
Remarkably decreased CAT expression was observed
when pcDNA-E2-proto was co-transfected (Figure 6,
column 2), indicating that HPV-2 E2 was able to inhibit
the activity of HPV-16 promoter P97. Similar to the
observations under the control of HPV-2 LCR, expres-
sions of either E2 with single A338V mutation (pcDNA-
E2-A338V, column 4) or A338V plus other four point
mutations (pcDNA-E2-Mut, column 3) resulted in sig-
nificantly more CAT expressions under the control of
HPV-16 LCR. As expected, transfection of pcDNA-E2-
M u t( - )( c o l u m n5 )w i t ho t h e rf o u rp o i n tm u t a t i o n s
except A338V still maintained the same repression on
P97 activity as that of pcDNA-E2-proto. These data sug-
gest that the A338V E2 mutant may reverse its regula-
tion activity on viral early promoters of HPVs with
similar upstream constructs.
Discussion
I nt h i ss t u d yw eh a v ep r o v i d e de v i d e n c ed a t at h a ta
naturally occurred mutation of A338V in HPV-2 E2
increases E2 DNA-binding capacity and reverses its
transcriptional regulation activity on the viral early pro-
moter. The effect of this mutation on the biological
functions of E2 seems to be very critical, since the other
four amino acid exchanges locate at the transactivation
domain and the hinge regions of E2 have little impact.
The E2 protein has the typical structure of transcrip-
tional regulator, which consists of a multiple-protein-
binding transactivation domain, a DNA-binding/dimeri-
zation domain, and a flexible linker [14]. Consistent
with other previous studies, our data confirm that
although the C-terminal segment of E2 alone has DNA-
binding capacity, lacking its N-terminal portion makes
the truncated E2 almost loss it’s of promoter repressor
activity. Our data indicate that the E2 N-terminal alone
works as a transcriptional activator, inducing about 1.5-
fold increased promoter activity. However, this positive
effect on the promoter is totally abolished in the context
of whole E2 protein. The substitution of L118S in the
E2 transactivation domain shows no influence on either
DNA-binding or promoter activity. The contribution of
E2 hinge region to its transcriptional regulator is
believed to be not essential [15], as three naturally
occurred mutations in this area together do not influ-
ence either the E2 DNA-binding or transcriptional
activation.
The structural analysis oft h eC - t e r m i n a lD B Df r o m
several PV E2 proteins, e.g. HPV-16, -18, -31 and bovine
papillomavirus (BPV-1), either alone or together with
TAD, suggest it to be a tight dimer upon DNA binding
[16,17]. The structure of E2 DNA-binding domain is
conserved among HPV families [18]. E2 DNA-binding
domains of HPV-2 and HPV-18 have 52% identity and
Figure 6 The influences of various HPV-2 E2 constructs on the
promoter activity under control of the LCR of HPV-16. The
relative CAT expression co-transfected with different E2 expressing
plasmids was evaluated. HeLa cells were transfected with 2 μgo f
plasmid pCAT-HPV16-LCR and 500 ng of either mock plasmid
(pcDNA3.1) or the plasmids for various E2 constructs (as indicated).
1 μg pCMV-b-galactosidase was transfected as internal control. Cells
were harvested 48 h after transfection and the expressions of CAT
and b-galactosidase were determined. The CAT expression each
preparation was normalized with its b-galactosidase value. The
relative CAT expressions are averaged from three independent
experiments and presented relative to that of pcDNA3.1. Data are
represented as mean ± SEM
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Page 8 of 13there is only one gap between the alignments (Figure
7A). With software Modeller9.5 and NAMD2.6, we have
constructed 3D structures of DNA-binding domains of
wild-type (338A) and mutant (338 V) E2 proteins using
the published crystal structure of HPV-18 E2 DNA-
binding domain as the template. The amino acid residue
338 locates in the region of beta barrel that is far away
from the helix region that binds to DNA (Figure 7B),
indicating that the influence of the mutation on DNA-
binding is not due to the direct alteration in the helix
region. However, in beta barrel structures the hydropho-
bic residues are oriented into the interior of the barrel
to form a hydrophobic core and the stability of theb-
barrel depends largely on the interaction of the inner
hydrophobic amino acid residues. The mutation from
Ala to Val at aa 338 increases the hydrophobic property
and subsequently stabilizes the dimeric structure of E2,
which is possibly responsible for the enhanced DNA
binding activities observed in the EMSA.
Previous study has showed that binding of the full-
length wild-type BPV-1 E2 protein to the LCR
sequences leads to formation of DNA loops and the
transcriptional activating domain of E2 is necessary for
this loop [19]. Such structure will result in the tissue-
specific enhancers shifting closer to the core
transcription complex for transcriptional activation
[20,21]. Meanwhile, some studies have indicated that
binding of the intact E2 to the LCR sequences may spa-
tially prevent the transcriptional machine to active the
promoter, which are the main molecular mechanism for
E2 transcriptional repression [22,23].
E2 has also been shown to be able to interact with
other cellular agents, e.g. Brd4, to regulate its transcrip-
tional activity [24]. The identification of Brd4 as a com-
ponent in a dominant form of E2 complexes indicates
that Brd4 may be the cofactor for HPV E2 repressor
function [25]. Apparently, Brd4 recruits E2 that in turn
prevents the recruitment of TFIID and pol II to the
HPV promoter [26]. Amino acid substitutions within
the E2 transactivation domain impaired both the tran-
scriptional activity and binding to Brd4 [27]. Further-
more, Brd4 is a host chromatin adaptor for
papillomavirus. The dimerization of the E2 is required
for efficient Brd4 binding [28]. The mutation from Ala
to Val at aa 338 of HPV-2 E2, which would change the
hydrophobicity and/or tertiary structure of E2, will lead
to a modification of its interaction with the chromatin,
and thus, modulates its transcriptional regulation activ-
ity. Although our data highlight a close correlation
between the increased activity for DNA-binding and the
enhanced activity for viral early promoters of the
mutated E2 protein, the exact mechanism remains
unclear.
Our data indicate that the DNA-binding capacity of
the C-terminal fragment of E2 is stronger than those
with the hinge region, and much stronger than the full-
length E2. Earlier study has found that besides the full-
length E2, bovine papillomavirus (BPV) E2 ORF also
encodes two other E2 peptides, E2-TR and E8/E2 pro-
teins [29]. These shorter E2 proteins contain the DNA
binding and dimerization domains of the C-terminus
and hinge region, but lack the transactivation domain.
Relative abundances of the truncated E2 proteins have
been observed in BPV transformed cells (the molar ratio
of E2:E2-TR:E8/E2 is 1:10:3) [30]. Expression of HPV-31
E8E2C protein has been reported to be able to inhibit
HeLa cell growth [31]. However, the transcriptional pro-
f i l e so fo t h e rH P VE 2O R F s ,r e g a r d l e s si nb e n i g no r
malignant cells, are rarely addressed. The fact that the
C-terminus E2 binds DNA stronger suggests that it is
more competitive than the full-length E2 in the cells.
Our study provides the evidence that HPV-2 E2,
regardless of wild-type or mutant (A338V), induces the
similar biological effectiveness under the controls of the
homologous and heterologous HPV LCRs. This suggests
that E2 protein may induce same regulative activity on
the viral early promoters from different HPVs with simi-
lar upstream components. Although there are more than
100 genotypes of HPVs involving in various human
Figure 7 Molecular modeling of HPV-2 E2 dimeric DNA-binding
domain (prototype and mutated forms). A: Sequence alignment
between HPV-2 E2 DNA-Binding domain and HPV-18’s (PDB: 1F9F
chain: D). There is only one gap between the alignment. In HPV-2
sequence, the A338V mutation is colored red. The secondary
structures are derived using the software DSSP. The arrows
represent b-strands, and zigzag lines indicate helices. B: The
modeled structures of HPV-2 E2 dimeric DNA-Binding domain.
Compared to the crystal structure of HPV-18 E2 DNA-Binding
domain (PDB: 1F9F), the two helix regions which bind DNA are
confirmed (colored cyan). The right structure is mutant form and
the residue 338 (Val) is colored red. The modeled structures show
that the residue 338 is located in the region of beta barrel
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Page 9 of 13benign or malignant proliferating diseases, the sequences
of viral genomes are relatively conservative. Hence, the
effectiveness of HPV-2 E2 may represent a common
property of HPVs’ E2 proteins.
In addition to the role in regulating viral transcription,
HPV E2 protein involves in enhancing E1-dependent
viral DNA replication and genome maintenance. In
HPV genomes the viral DNA replication initiation site
co-localizes with the viral transcription region. However,
the regulative function of E2 in viral DNA replication is
far from understood compared with its role in transcrip-
tional regulation. Although the point mutations in TAD
and in hinge region within this E2 mutant do not affect
DNA-binding and transcriptional regulation, their influ-
ence on viral genome replication cannot be excluded.
Sequences analyses of this variant HPV-2 strain have
also identified several point mutations in its E1 ORF.
Further studies of viral genome replication will help
explore the inconvenient reason of such huge verrucae
vulgaris.
Conclusions
Our study provides evidence that HPV-2 E2 with Ala to
Val mutation at aa 338 is critical for E2 DNA-binding
and its transcriptional regulation. The binding abilities
of E2 proteins with A338V to either an artificial probe
containing with two E2 binding sites or HPV-2 and
HPV-16 promoter-proximal LCR sequences were signifi-
cantly stronger than that of HPV-2 prototype E2.
Furthermore, co-expression of the E2 constructs con-
taining A338V mutation induces higher activities on
heterologous HPV-16 early promoter P97 than that of
prototype E2.
Methods
Plasmids construction
Mammalian expression plasmid pcDNA-E2-proto con-
taining the whole E2 sequences of HPV-2 prototype,
plasmid pcDNA-E2-Mut containing the whole E2
sequences of isolate 1 and CAT reporter plasmid
pCAT-LCR(L) containing HPV-2 prototype LCR
sequence (from nt 6934 to 134) were generated pre-
viously [13]. The plasmid pCAT-LCR-HPV16 containing
HPV-16 LCR was generated previously [32]. Sited-direc-
tion mutation PCR was performed using pcDNA-E2-
proto or pcDNA-E2-Mut as the templates to generate
various E2 sequences with one to four point mutations.
Table 1 summarized the primers used in PCR, in which
the primers amplifying whole E2 ORF (from nt 2685 to
3860), E2 N-segment (from nt 2685 to 3279) and E2 C-
segment (from nt 3618 to 3860) contained a Hind III
site in the up-steam and Bam HI site in the down-steam
primers.
PCR amplification was performed in 25 μlo far e a c -
tion mixture containing 2.5 U of Taq DNA polymerase
(TaKaRa, Dalian, China), 20 mM dNTP, 150 ng of each
mixture of HPV-2 E2 specific primers at the cycle con-
dition of denaturing at 94°C for 30 s, annealing at 58°C
for 30 s, extending at 72°C for 1 min, totally 30 cycles,
respectively. Briefly, to construct the E2-sequence con-
taining single point-mutation including the mutants of
L118S, S235P or A338V, two separated PCR amplifica-
tions were conducted using pcDNA-E2-proto as the
templates, with the primer mixture of E2-up with 118-
down, 235-down or m338-down, and the mixture of E2-
down with 118-up, 235-up or m338-up, respectively.
After purified, two individual PCR products were mixed
and annealed, and the sequence covering whole E2 ORF
of each mutant was constructed by another PCR ampli-
fication with primers E2-up and E2-down, generating
E2-L118S, E2-S235P and E2-A338V, respectively. To
generate E2-sequence containing two point-mutations of
L118S and S235P, two separated PCRs were conducted
based on the sequence of E2-L118S, with the primes E2-
up and 235-down, as well as 235-up and E2-down,
respectively. The whole E2 sequence of this mutant was
obtained with the same protocol above, generating E2-
L118S/S235P. To construct E2-sequence containing
other four mutations except A338V, the PCR reactions
were separately performed using E2-Mut sequence as
the template, with the primer E2-up and 338-down, as
well as 338-up and E2-down. The whole E2 sequence
Table 1 The primers for site-directed mutation PCR
Primers The sequence of the primers Enzyme
site
E2-up 5’AAGCTTATGGAAACACTGGCGAACCGT3’ Hind III
E2-down 5’GGATCCTTATACAAATGCAGACATATACCC3’ BamHI
E2N-down 5’GGATCCTTATGATTCTGCTGAGGC3’ BamHI
E2C-up 5’CTTAAGGTGGCTGGGACTGTTATTCAC3’ Hind III
118-up 5’CAGTACTAGTGAAATTTGATGGCAGC3’ \
118-down 5’GCTGCCATCAAATTTCACTAGTACTG3’ \
235-up 5’CAGAACCAACAGGAGCAGGAAG3’ \
235-down 5’GTGGAGGACACCCTGGCATAC3’ \
338-up 5’GTATGCCAGGGTGTCCTCCAC3’ \
338-down 5’GTGGAGGACACCCTGGCATAC3’ \
m338-up 5’GTATGTCAGGGTGTCCTCCAC3’ \
m338-down 5’GTGGAGGACACCCTGACATAC3’ \
E2-P-up 5’GGATCCATGGAAACACTGGCGAACCGT3’ BamHI
E2N-P-
down
5’GAATTCTTATGATTCTGCTGAGGC3’ EcoRI
E2C-P-up 5’GGATCCGTGGCTGGGACTGTTATTCAC3’ BamHI
E2-P-down 5’GAATTCTTATACAAATGCAGACATATACCC3’ EcoRI
E2-P-117-up 5’GGATCCTACATCCGCATCTGTGTCTAG3’ BamHI
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E2-Mut (-). E2 N-segment (from nt 2685 to 3279) and
E2 C-segment (from nt 3618 to 3860) were generated by
PCR with respective primer mixtures. The generated E2
sequences were cloned into plasmid pMD18-T. After
verified with sequencing assays, various E2 segments
were released from cloning vectors and subcloned into
pcDNA3.1, generating mammalian expressing recombi-
nant plasmids pcDNA-E2 (Figure 1A).
To construct the different HPV-2 E2 prokaryotic
expressing plasmids, including E2 of prototype (E2), E2
of isolate 1 (E2-Mut) and various mutated E2, three
lengths of E2 sequences, including the full-length E2
ORF (from aa 1 to 391, FL), the sequence starting from
hinge region to the end (from aa 197 to 391, HC) and
C-terminal segment (from aa 311 to 391, C), were gen-
erated by PCR technique with different primer mixtures,
using individual pcDNA-E2 as the templates. The PCR
products were cloned into plasmid pMD18-T and sub-
cloned into a (GST) expression vector pGEX-2 T, gener-
ating various plasmids pGST-E2 (Figure 2A).
Cell line, transfection and CAT assay
The human cervical cancer cell lines HeLa were main-
tained in Dulbecco’s modified Eagle’sm e d i u m( I n v i t r o -
gen) with 10% fetal calf serum (HyClone). C33A and
SiHa cell lines were maintained in ATCC-formulated
Eagle’s Minimum Essential Medium (Catalog No.30-
2003) with 10% fetal calf serum. Cells were plated into
60 mm 6-well plates (Falcon, Japan) one day before
transfection. 2 μg of plasmid pCAT-LCR were trans-
fected with Lipofectamine 2000 transfection reagent
(Invitrogen, USA), together with 1 μg of pCMV-b-galac-
tosidase as internal control. To evaluate the effectiveness
of E2 protein on the promoter activity, various E2
expression plasmids (500 ng) were co-transfected into
cells. Cells were harvested at 48 h after transfection.
CAT expressions were measured quantitatively using a
CAT ELISA kit (Roche, Switzerland), according to the
instruction manual. The expression of b-galactosidase
activity was determined using O-nitrophenyl-b-D-galac-
topyranoside (ONPG) as a colorimetric substrate. HPV-
2 promoter activities were determined by calculating the
rates of CAT and b-galactosidase values. Each experi-
ment was independently performed for three to five
times.
Western blots
HeLa and C33A cells transfected with 500 ng various E2
expressing plasmids, together with or without 2 μg
pCAT-LCR, were harvested 24, 48 and 72 h post-trans-
fection. Cells were pelleted by short centrifugation and
suspended in the lysis buffer (10 mM Tris-HCl, pH 7.8,
0.5% sodiumdeodycholate, 0.5% Nonidet P-40, 100 mM
NaCl, 10 mM EDTA), supplemented with complete pro-
teasomal inhibitor mixture. Cell lysates were separated
by 15% SDS-PAGE and electro-transferred onto nitro-
cellulose membranes. After blocking with 5% nonfat-
dried milk in PBS (phosphate buffered saline, pH 7.6)
o v e r n i g h ta t4 ° C ,t h em e m b r a n e sw e r ei n c u b a t e dw i t h
1:1,000 HPV E2 specific monoclonal antibody at room
temperature (RT). After washing with PBST (phosphate
buffered saline, pH 7.6, containing 0.05% Tween-20), the
membranes were incubated with 1:5,000 horseradish
peroxidase (HRP)-conjugated anti-mouse antibody. The
E2 protein signals were visualized by ECL kit (PE
Applied Biosystems, USA). To reuse the blotted mem-
brane, the developed membrane was treated in the
Restore Western Blot Stripping Buffer (Thermo, USA)
for 10 min at RT. 1:1,000 mAb anti-human b-actin
(Santa Cruz, USA) and HRP-conjugated anti-mouse
antibody were used to identify b-actin protein. ECL kit
was used to visualize the signals.
Expression and purification of E2 proteins
The recombinant prokaryotic proteins tagged with GST
were bacterially expressed in E. coli BL21 and purified
with Glutathione Sepharose 4B Agarose (Pharmacia,
USA) according the protocol described in our previous
study [33]. The purities of the purified proteins were
verified by 15% SDS-PAGE.
Electrophoretic mobility shift assays (EMSA)
For EMSA, single DNA oligos labeled with biotin that
covered two E2 binding sites (HPV-E2BS)
ACCGAAAACGGTCAGACCGAATTCGGTTGT3’ and
5’ACAACCgAATTCGGTCTGACCGTTTTCGGTCA-
CAC3’) and HPV-16 (5’GGCGTAACCGAAATCGGTT-
GAACCGAAACCGGTT3’ and 5’AACCGGTTTCGGTT
CAACCGATTTCGGTTACGCC3’) were synthesized
based on the sequences in GenBank. After denaturing
by heating, two signal DNA oligos were annealed at RT
to a double-stranded DNA probe. 12.5 to 250 fM bio-
tin-labeled oligonucleotide probes were mixed with var-
ious amounts of different E2 proteins in 20 μlb i n d i n g
buffer (10 mM Tris, 50 mM KCl, 1 mM DTT, pH 7.5)
at RT for 20 min. For competition experiments, biotin-
labeled oligo HPV-E2BS was competed with 50-, 100-
and 500-fold excess of unlabeled homologous oligo or
500-fold excess of unlabeled heterologous oligo (T7 pro-
moter double-stranded sequences). For supershift
EMSA, 7 μg recombinant HPV-2 E2-FL was incubated
with mAb against HPV-E2 at RT for 30 min, prior to
mixing with biotin-labeled oligo HPV-E2BS. DNA-pro-
tein complexes were separated from unbound probe in
a 6.5% non-denaturing polyacrylamide gel and visualized
by LightShift
® Chemiluminescent EMSA Kit (Pierce,
USA) according to the manufacturer’s instruction.
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computer-assisted software Image Total Tech (Pharma-
cia, USA). The image was scanned with Typhoon (Phar-
macia, USA), digitalized and saved as TIF format.
Structure analysis
The 3D structures of prototype and mutated HPV-2 E2
DNA-binding domain were modeled based on the
existed crystal structure of HPV E2 with the help of
software Modeller9.5 and NAMD2.6 (optimize the
structure by energy minimization). The quaternary
structure of HPV-18 (PDB: 1F9F) was choose as the
template.
Molecular modeling
Molecular models of prototype and mutated HPV-2 E2
DNA-binding domain were constructed using the
homology modeling software Modeller v9.5 [8]. The clo-
sely related structure of HPV-18 E2 DNA-binding
domain (PDB: 1F9F) [34] was used as the template. The
resulting structure files were subjected to energy mini-
mization using NAMD2.6 [18].
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